Advertisement
OtherArticle

Assessment of the Potential for Veverimer Drug-Drug Interactions

Dawn Parsell, Jun Shao, Robert Guttendorf, Vandana Mathur, Elizabeth Li, Yick Sen Wu, Li Tsao, Scott Tabakman, Yuri Stasiv, Angela Lee, Kalpesh Biyani and Gerrit Klaerner
Drug Metabolism and Disposition May 24, 2021, DMD-AR-2021-000366; DOI: https://doi.org/10.1124/dmd.121.000366

Data Supplement

  • Supplemental Data -

    Mean (SD) Plasma Total Dabigatran Concentration Profile over Time (Linear Scale)Supplemental Methods 

    Supplemental Table 1 - Anionic Probes (Test Acids).

    Supplemental Table 2 - Gastric pH Study Subject Disposition.

    Supplemental Table 3 - Gastric pH Study Demographics and Baseline Characteristics

    Supplemental Table 4 -Test Drugs with pH-Dependent Solubility

    Supplemental Table 5 - Exclusion Criteria for Genotyping

    Supplemental Table 6 - DDI Study Subject Disposition

    Supplemental Table 7 - DDI Study Demographics and Baseline Characteristics

    Supplemental Table 8 - Human DDI Study Pharmacokinetics Analyses - Summary Statistics

    Supplemental Table 9 - Summary Statistics for INR AUC0-0168 and INRmax in the Warfarin DDI Study

    Supplemental Table 10 - ANOVA Comparison of Geometric Least Square Means for INR AUC0-0168 and INRmax in the Warfarin DDI Study

    Supplemental Figure 1 - Gastric pH Study Design Schematic

    Supplemental Figure 2 - Drug-Drug Interaction Study Design (Furosemide, Aspirin, Warfarin)

    Supplemental Figure 3 - Drug-Drug Interaction Study Design (Dabigatran)

    Supplemental Figure 4 - Effect of Food: Water Administered under Fasting vs. Fed Conditions

    Supplemental Figure 5 - Effect of Omeprazole: Water Administered under Fasting Conditions Without vs. With Omeprazole

    Supplemental Figure 6 - Mean (SD) Plasma Furosemide Concentration Profile over Time (Linear Scale)

    Supplemental Figure 7 - Mean Plasma Furosemide Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 8 - Mean (SD) Plasma Acetylsalicylic Acid Concentration Profile over Time (Linear Scale)

    Supplemental Figure 9 - Mean Plasma Acetylsalicylic Acid Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 10 - Mean (SD) Plasma Salicylic Acid Concentration Profile over Time (Linear Scale)

    Supplemental Figure 11 - Mean Plasma Salicylic Acid Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 12 - Mean (SD) Plasma R-Warfarin Concentration Profile over Time (Linear Scale)

    Supplemental Figure 13 - Mean Plasma R-Warfarin Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 14 - Mean (SD) Plasma S-Warfarin Concentration Profile over Time (Linear Scale)

    Supplemental Figure 15 - Mean Plasma S-Warfarin Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 16 - Mean (SD) Plasma Total Dabigatran Concentration Profile over Time (Linear Scale)

    Supplemental Figure 17 - Mean Plasma Total Dabigatran Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 18 - Mean (SD) Plasma Free Dabigatran Concentration Profile over Time (Linear Scale)

    Supplemental Figure 19 - Mean Plasma Free Dabigatran Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 20 - Mean (SD) International Normalized Ratio over Time (Linear Scale)

    Supplemental Figure 21 - Mean International Normalized Ratio over Time (Log-Linear Scale)

  View article